LUND, SWEDEN--(MARKET WIRE)--Jun 7, 2007 -- Jerusalem, Israel and Lund, Sweden, June 7, 2007 - Teva Pharmaceutical Industries Ltd. (NasdaqGS:TEVA - News) and Active Biotech AB (OMX NORDIC: ACTI) today announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS). The studies will now begin following the successful conclusion of a second phase II study and the outcome of discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).
